ROVI informs on the evaluation process to obtain marketing authorisation for Risvan®

Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults


ROVI informs on the evaluation process to obtain marketing authorisation for Risvan®

  • The United States Food and Drug Administration (FDA) has issued a Complete Response Letter. In this letter, the FDA informs ROVI that it considers the responses to the evaluation of the Risvan® dossier to be complete and makes no additional observations.
  • The letter states that ROVI must close the observations made by the FDA during its inspection in May 2023. ROVI will submit a response to reinitiate the procedure providing details of the responses that have already been filed. ROVI will then await a further notification from the FDA with the estimated User Fee Goal Date for the closure of the procedure, which is expected to be in February 2024.
  • There are no observations that have not yet been resolved by ROVI’s suppliers.
Average: 3.7 (3 votes)
 
Related
​The new facility has meant an investment of 11 million euros This new line, which has now been authorised to commence commercial...
3 min
20/06/2024
Operating revenue was 151.2 million euros in the first quarter of 2024, a 25% decrease on the first quarter of 2023, mainly due...
4 min
08/05/2024
Agreement to manufacture pre-filled syringes for a global pharmaceutical company Production will take place on one state-of-the-art...
3 min
25/04/2024